IgGenix is a biotechnology company based in South San Francisco that is developing first-in-class therapies for the millions of people who suffer from food, non-food and other severe allergies. The company uses a proprietary antibody-based therapeutic platform that allows it to capture and analyze B cells that express allergen-binding IgE antibodies to specific allergens. The company then infuses those B cells with powerful immune-modulating activities that turn them into IgG antibodies that can suppress allergic reactions.